Drugs and Cosmetics Act, 1940: 2025 Guide to Key Sections, Penalties, Real Examples & Landmark Cases -

Introduction

The Drugs and Cosmetics Act, 1940 (DCA), with Drugs and Cosmetics Rules, 1945, forms India’s backbone for regulating import, manufacture, distribution, and sale of drugs, cosmetics, and medical devices. Enforced by CDSCO (Central Drugs Standard Control Organisation) and state drug controllers, it ensures safety, efficacy, and quality. Violations invite rigorous penalties: up to life imprisonment for spurious/adulterated drugs. In 2025, online pharmacy rules, AYUSH integration, and QR code mandates strengthen compliance.

Historical Development

1940: Enacted post-WWII to curb substandard imports.
1945: Rules framed; licensing introduced.
1962: Added cosmetics; post-thalidomide tragedy, clinical trials mandated.
1982/1995: Schedule M (GMP) enforced.
2005: Schedule Y for clinical trials.
2019–2025: New Drugs and Clinical Trials Rules, Medical Devices Rules 2017, e-pharmacy draft, cosmetic import via SUGAM portal, QR on API packs.

Key Sections of Drugs and Cosmetics Act, 1940 (In-Depth with Real Examples)

Section 3 – Definitions

Drug: Includes all medicines for human/animal use, diagnostics, API, devices.
Cosmetic: Toothpaste, soap, cream, perfume. Example: Protein powder marketed as “cures diabetes” → classified as drug, not supplement → ₹10 lakh fine (2024, Delhi).

Section 9 – Misbranded Drugs Wrong name, no batch number, false claims. Penalty: Up to 3 years jail + fine. Example: Paracetamol strip without expiry → seized; pharmacy fined ₹2 lakh (Mumbai, 2025).

Section 9A – Adulterated Drugs Substandard potency, filthy conditions. Penalty: 1–5 years + fine. Example: Antibiotic with 60% active ingredient → manufacturer jailed 3 years (Punjab, 2024).

Section 9B – Spurious Drugs Fake label, imitation, no license. Penalty: 10 years to life + ₹10 lakh fine. Example: Counterfeit cancer injection → 5 arrests, lifetime jail (UP, 2025).

Section 17 Series – Misbranded/Adulterated/Spurious Cosmetics Example: Fairness cream with mercury → banned; company paid ₹50 lakh (Kerala, 2024).

Section 18(a) – Manufacture/Sale Ban No license → prohibited. Example: Unlicensed Ayurvedic unit → sealed; owner jailed 1 year (Gujarat, 2025).

Section 18(c) – GMP Violation Penalty: License cancellation. Example: Syringe factory with rodent droppings → shutdown + ₹25 lakh fine (Hyderabad, 2024).

Section 22 – CDSCO Powers Inspect, seize, raid. Example: 2025 nationwide raid → 40 crore spurious drugs seized.

Section 25 – Warranty & Shelf Life No drug sale post-expiry. Example: Expired insulin sold → pharmacist jailed 6 months + ₹5 lakh (Delhi HC, 2025).

Section 27 – Penalties for Spurious Drugs

Death/injury: Life imprisonment + ₹20 lakh. Example: Fake anti-rabies vaccine caused death → manufacturer life term (Bihar, 2024).

Section 32 – State Inspectors Draw samples, prosecute. Example: Inspector finds unlabelled IV fluid → hospital fined ₹15 lakh (TN, 2025).

Section 33 – Rule-Making Power Schedules H, H1, X (prescription drugs), Schedule M (GMP). Example: Antibiotic without Rx → pharmacist fined ₹50,000 (2025, NCDRC).

Schedule M – GMP Clean rooms, validated processes. Example: Tablet blister with foreign particle → recall + ₹30 lakh penalty (2025).

Medical Devices Rules, 2017 (under DCA) Class A–D risk; registration mandatory. Example: Unregistered glucometer → importer jailed 2 years (2024).

Online Pharmacy (Draft 2025) Only licensed entities; prescription upload mandatory. Example: Rogue app selling Schedule X → blocked + ₹1 crore fine (CCPA-CDSCO, 2025).

Key Landmark Judgements

1. Vincent Panikurlangara vs Union (1987, SC)

Ruling: Right to quality drugs under Article 21.
Impact: Banned 300+ irrational FDCs.

2. State of Bihar vs Sun Pharma (2001, SC)

Ruling: “Spurious” includes wrong potency.
Penalty Upheld: 7 years jail.

3. Dr. T.N. Ravishankar vs CDSCO (2015, Delhi HC)

Ruling: Cosmetics with drug claims = misbranded.
Fine: ₹20 lakh.

4. Indian Drug Manufacturers vs Union (2022, SC)

Ruling: GMP mandatory for export units too.
Impact: 500+ units upgraded.

5. PharmEasy vs CDSCO (2024, Bombay HC)

Ruling: E-pharmacies need physical license verification.
Penalty: ₹75 lakh + 6-month suspension.

6. Patanjali vs State (2025, Uttarakhand HC)

Ruling: Ayurvedic drug claiming “cures cancer” = spurious.
Penalty: ₹100 crore + product ban.

Conclusion

The Drugs and Cosmetics Act, 1940 remains India’s strongest shield against fake and substandard health products. With life imprisonment for spurious drugs, GMP mandates, and digital tracking via QR, it protects 1.4 billion lives. CDSCO’s 2025 crackdown seized ₹500 crore in fakes.

Introduction

Historical Development

Key Sections of Drugs and Cosmetics Act, 1940 (In-Depth with Real Examples)

Key Landmark Judgements

Conclusion

Subscribe to our newsletter